Cover Image
Market Research Report

Europe Glucose Monitoring System Market Forecast 2019-2027

Published by Inkwood Research Product code 429442
Published Content info 140 Pages
Delivery time: 2-3 business days
Price
Back to Top
Europe Glucose Monitoring System Market Forecast 2019-2027
Published: June 10, 2019 Content info: 140 Pages
Description

KEY FINDINGS

The Europe Continuous Glucose Monitoring System (CGMS) market is expected to rise from $XX million in 2018 to $XX million by 2027, exhibiting a CAGR of 32.91% over the forecast period of 2019-2027.

The Europe Self-Monitoring of Blood Glucose (SMBG) market is expected to rise from $XX million in 2018 to $XX million by 2027, at a CAGR of 5.42% over the forecasted period.

MARKET INSIGHTS

The number of diabetic patient pool in the European regional market have increased tremendously over the past few years. This, in turn, increased the need for awareness amongst the people about the advanced CGM devices to monitor glucose levels and manage insulin delivery. Also, there was a need for improvement of health infrastructure for the same. Each of the 28 countries in Europe has its own system for approval of distributing and supplying medical devices. The German market dominated the European scene in 2018. However, the French market is expected to rise with the highest CAGR over the forecast period. This is due to the French's health infrastructure and services being one of the best in the world.

COMPETITIVE INSIGHTS

Companies like Abbott, Senseonics Inc., Terumo, GlySens Inc., Tandem Diabetes Care, Medtronic, Morepen Laboratories Ltd., B Braun Melsungen AG, Becton Dickinson And Company, Dexcom, Wockhardt, Ypsomed, I-Sens Inc., Nemaura Medical Inc., Insulet Corp., ARKRAY Inc., Roche Diagnostics, Apex Biotechnology Corp., Johnson and Johnson, and Ascensia are leading in this region.

Table of Contents
Product Code: 2951

Table of Contents

1. RESEARCH SCOPE

  • 1.1. STUDY GOALS
  • 1.2. SCOPE OF THE STUDY MARKET
  • 1.3. WHO WILL FIND THIS REPORT USEFUL?
  • 1.4. STUDY AND FORECASTING YEARS

2. RESEARCH METHODOLOGY

  • 2.1. SOURCES OF DATA
  • 2.2. BOTTOM-UP APPROACH
  • 2.3. TOP-DOWN APPROACH
  • 2.4. DATA TRIANGULATION

3. EXECUTIVE SUMMARY

  • 3.1. MARKET SUMMARY
  • 3.2. KEY FINDINGS
    • 3.2.1. CGMS MARKET IS ANTICIPATED TO BE A FASTEST GROWING MARKET
    • 3.2.2. SELF-MONITORING OF BLOOD GLUCOSE HAS HUGE MARKET OPPORTUNITY
    • 3.2.3. COLLABORATION OF SIGNIFICANT COMPANIES TO DEVELOP INTEGRATED CGMS-ENABLED INSULIN PUMPS

4. MARKET DYNAMICS

  • 4.1. MARKET SCOPE & DEFINITION
  • 4.2. MARKET DRIVERS
    • 4.2.1. RISE IN THE INCIDENCE OF DIABETES
    • 4.2.2. INCREASING FOCUS ON RESEARCH AND DEVELOPMENT
    • 4.2.3. TECHNOLOGY INTEGRATION
    • 4.2.4. INCREASED AFFORDABILITY OF CGMS AND SMBG
    • 4.2.5. TECHNOLOGICAL ADVANCES IN GMS DEVICES
    • 4.2.6. AWARENESS AMONG THE GENERAL POPULATION
  • 4.3. MARKET RESTRAINTS
    • 4.3.1. HINDERANCE FROM GOVERNMENT REGULATIONS
    • 4.3.2. INADEQUATE REIMBURSEMENT OPTIONS FOR CONTINUOUS GLUCOSE MONITORING DEVICES
    • 4.3.3. LACK OF AWARENESS OF THE DIAGNOSTIC OPPORTUNITIES
  • 4.4. MARKET OPPORTUNITIES
    • 4.4.1. RISING EMERGING TECHNOLOGIES
  • 4.5. MARKET CHALLENGES
    • 4.5.1. INTENSE COMPETITION AMONG VENDORS
    • 4.5.2. INACCURACY IN READING OF GMS DEVICES
    • 4.5.3. INCREASINGLY STRINGENT GOVERNMENT REGULATIONS

5. CGMS MARKET BY COMPONENT TYPE

  • 5.1. SENSORS
  • 5.2. TRANSMITTERS AND RECEIVERS
  • 5.3. INSULIN PUMP

6. CGMS MARKET BY END-USERS

  • 6.1. HOME SETTINGS
  • 6.2. DIAGNOSTICS AND CLINICS
  • 6.3. HOSPITALS

7. CGMS MARKET BY DEMOGRAPHICS

  • 7.1. ADULT POPULATION (>14YEARS)
  • 7.2. CHILD POPULATION (≤14YEARS)

8. SMBG MARKET OVERVIEW

9. SMBG MARKET BY COMPONENT TYPE

  • 9.1. TEST STRIPS
  • 9.2. GLUCOSE METER
  • 9.3. LANCETS

10. SMBG MARKET BY END-USER

  • 10.1. HOME SETTINGS
  • 10.2. CLINICAL
  • 10.3. HOSPITAL

11. SMBG MARKET BY APPLICATION

  • 11.1. TYPE 1 DIABETES
  • 11.2. TYPE 2 DIABETES
  • 11.3. GESTATIONAL DIABETES

12. KEY ANALYTICS

  • 12.1. PORTER'S 5 FORCE ANALYSIS
    • 12.1.1. THREAT OF NEW ENTRANT
    • 12.1.2. THREAT OF SUBSTITUTE PRODUCTS OR SERVICES
    • 12.1.3. BARGAINING POWER OF BUYERS
    • 12.1.4. BARGAINING POWER OF SUPPLIER
    • 12.1.5. INTENSITY OF COMPETITIVE RIVALRY
  • 12.2. KEY BUYING CRITERIA
  • 12.3. KEY TRENDS
    • 12.3.1. DEVELOPMENT OF HIGH-QUALITY WEARABLE DEVICES
    • 12.3.2. MOBILE HEALTHCARE MAKING THE DEVICES MORE USER-FRIENDLY
    • 12.3.3. INCREASING EFFORTS TOWARDS SPREAD OF AWARENESS
    • 12.3.4. INCREASE IN NON-INVASIVE DEVICES
    • 12.3.5. ENERGY HARVESTING TECHNOLOGY FOR UNINTERRUPTED USAGE
  • 12.4. REGULATION OF BLOOD SUGAR
  • 12.5. VALUE CHAIN ANALYSIS
  • 12.6. OPPORTUNITY MATRIX

13. REGIONAL ANALYSIS

  • 13.1. EUROPE
    • 13.1.1. THE UNITED KINGDOM
      • 13.1.1.1. THE UNITED KINGDOM HEALTH AND HEALTHCARE
      • 13.1.1.2. THE UNITED KINGDOM HEALTHCARE PROVISION
      • 13.1.1.3. THE UNITED KINGDOM PRIVATE SECTOR INVOLVEMENT
      • 13.1.1.4. THE UNITED KINGDOM PHARMACEUTICALS
    • 13.1.2. FRANCE
      • 13.1.2.1. FRANCE HEALTH AND HEALTHCARE
      • 13.1.2.2. FRANCE HEALTHCARE PROVISION
    • 13.1.3. GERMANY
      • 13.1.3.1. GERMANY HEALTH AND HEALTHCARE
      • 13.1.3.2. GERMANY PHARMACEUTICAL MARKET
    • 13.1.4. ITALY
      • 13.1.4.1. ITALY HEALTH AND HEALTHCARE
      • 13.1.4.2. ITALY HEALTHCARE PROVISION
      • 13.1.4.3. ITALY PHARMACEUTICAL MARKET
    • 13.1.5. SPAIN
      • 13.1.5.1. SPAIN HEALTH AND HEALTHCARE
      • 13.1.5.2. SPAIN HEALTHCARE PROVISION
      • 13.1.5.3. SPAIN PHARMACEUTICAL SERVICES
    • 13.1.6. RUSSIA
      • 13.1.6.1. RUSSIA HEALTH AND HEALTHCARE
      • 13.1.6.2. RUSSIA PHARMACEUTICAL SERVICES
    • 13.1.7. REST OF EUROPE (ROE)

14. COMPETITIVE LANDSCAPE

  • 14.1. MARKET POSITION ANALYSIS
  • 14.2. COMPANY PROFILES
    • 14.2.1. ABBOTT
    • 14.2.2. APEX BIOTECHNOLOGY CORP.
    • 14.2.3. ARKRAY INC.
    • 14.2.4. ASCENSIA
    • 14.2.5. B BRAUN MELSUNGEN AG
    • 14.2.6. BECTON DICKINSON AND COMPANY
    • 14.2.7. DEXCOM
    • 14.2.8. GLYSENS INC.
    • 14.2.9. INSULET CORP
    • 14.2.10. I-SENS INC.
    • 14.2.11. JOHNSON AND JOHNSON
    • 14.2.12. MEDTRONIC
    • 14.2.13. MOREPEN LABORATORIES LTD.
    • 14.2.14. NEMAURA MEDICAL INC.
    • 14.2.15. ROCHE DIAGNOSTICS
    • 14.2.16. SENSEONICS INC.
    • 14.2.17. TANDEM DIABETES CARE
    • 14.2.18. TERUMO
    • 14.2.19. WOCKHARDT
    • 14.2.20. YPSOMED

LIST OF TABLES

  • TABLE 1 EUROPE CGMS MARKET 2019-2027($ MILLION)
  • TABLE 2 EUROPE SMBG MARKET 2019-2027 ($ MILLION)
  • TABLE 3 DIABETES PREVALENCE IN EUROPE 2015-2040 (MILLIONS)
  • TABLE 4 EUROPE CGMS MARKET BY COMPONENT TYPE 2019-2027($ MILLION)
  • TABLE 5 EUROPE CGMS SENSORS MARKET 2019-2027 ($ MILLION)
  • TABLE 6 EUROPE CGMS TRANSMITTERS AND RECEIVERS MARKET 2019-2027 ($ MILLION)
  • TABLE 7 EUROPE CGMS INSULIN PUMP MARKET 2019-2027 ($ MILLION)
  • TABLE 8 EUROPE CGMS MARKET BY END-USER 2019-2027 ($ MILLION)
  • TABLE 9 EUROPE CGMS HOME SETTINGS MARKET 2019-2027 ($ MILLION)
  • TABLE 10 EUROPE CGMS DIAGNOSTICS AND CLINICAL MARKET 2019-2027 ($ MILLION)
  • TABLE 11 EUROPE CGMS HOSPITAL MARKET 2019-2027 ($ MILLION)
  • TABLE 12 EUROPE CGMS MARKET BY DEMOGRAPHICS 2019-2027 ($ MILLION)
  • TABLE 13 EUROPE CGMS ADULT POPULATION (>14YEARS) MARKET 2019-2027 ($ MILLION)
  • TABLE 14 EUROPE CGMS CHILD POPULATION (≤14YEARS) MARKET 2019-2027 ($ MILLION)
  • TABLE 15 IMPORTANT ASPECTS FOR THE USE OF SMBG DEVICES IN HOME-CARE SETTINGS
  • TABLE 16 SMBG STRIPS USAGE SCENARIO IN SELECTED COUNTRIES IN AMERICAS
  • TABLE 17 PRODUCT MATRIX FOR LANCETS
  • TABLE 18 EUROPE SMBG MARKET BY COMPONENT TYPE 2019-2027 ($ MILLION)
  • TABLE 19 EUROPE SMBG LANCETS MARKET 2019-2027 ($ MILLION)
  • TABLE 20 EUROPE SMBG MARKET BY END-USER 2019-2027 ($ MILLION)
  • TABLE 21 EUROPE SMBG HOME SETTING MARKET 2019-2027 ($ MILLION)
  • TABLE 22 EUROPE SMBG CLINICAL MARKET 2019-2027 ($ MILLION)
  • TABLE 23 EUROPE SMBG HOSPITAL MARKET 2019-2027 ($ MILLION)
  • TABLE 24 EUROPE SMBG MARKET BY APPLICATION 2019-2027 ($ MILLION)
  • TABLE 25 EUROPE SMBG TYPE 1 DIABETES MARKET 2019-2027 ($ MILLION)
  • TABLE 26 EUROPE SMBG TYPE 2 DIABETES MARKET 2019-2027 ($ MILLION)
  • TABLE 27 EUROPE SMBG GESTATIONAL DIABETES MARKET 2019-2027 ($ MILLION)
  • TABLE 28 EUROPE SMBG MARKET 2019-2027 ($ MILLION)
  • TABLE 29 EUROPE CGMS MARKET 2019-2027 ($ MILLION)
  • TABLE 30 AVERAGE PRICES IN UK FOR GLUCOSE TEST STRIPS, LANCETS AND GLUCOSE METER
  • TABLE 31 THE UNITED KINGDOM SMBG SALES CHANNEL 2019-2027 ($ MILLION)
  • TABLE 32 AVERAGE PRICES IN GERMANY FOR GLUCOSE TEST STRIPS, LANCETS AND GLUCOSE METER
  • TABLE 33 GERMANY SMBG SALES CHANNEL 2019-2027 ($ MILLION)
  • TABLE 34 SMBG COMPANY MARKET POSITION ANALYSIS 2018
  • TABLE 35 CGMS COMPANY MARKET POSITION ANALYSIS 2018

LIST OF FIGURES

  • FIGURE 1 EUROPE CGMS MARKET SHARE BY COMPONENT TYPE 2018 & 2027 (%)
  • FIGURE 2 EUROPE CGMS MARKET BY SENSORS 2019-2027($ MILLION)
  • FIGURE 3 EUROPE CGMS MARKET BY TRANSMITTERS AND RECEIVERS 2019-2027($ MILLION)
  • FIGURE 4 EUROPE CGMS MARKET BY INSULIN PUMP 2019-2027($ MILLION)
  • FIGURE 5 EUROPE CGMS SHARE BY END-USER 2018 & 2027 (%)
  • FIGURE 6 EUROPE CGMS MARKET BY HOME SETTING 2019-2027($ MILLION)
  • FIGURE 7 EUROPE CGMS MARKET BY DIAGNOSTICS AND CLINICAL 2019-2027($ MILLION)
  • FIGURE 8 EUROPE CGMS MARKET BY HOSPITAL 2019-2027($ MILLION)
  • FIGURE 9 EUROPE CGMS MARKET SHARE BY DEMOGRAPHICS 2018 & 2027 (%)
  • FIGURE 10 EUROPE CGMS MARKET BY ADULT POPULATION (>14YEARS) 2019-2027($ MILLION)
  • FIGURE 11 EUROPE CGMS MARKET BY CHILD POPULATION (≤14YEARS) 2019-2027($ MILLION)
  • FIGURE 12 EUROPE SMBG MARKET SHARE BY COMPONENT TYPE 2018 & 2027 (%)
  • FIGURE 13 EUROPE SMBG MARKET BY TEST STRIPS 2019-2027 ($ MILLION)
  • FIGURE 14 EUROPE SMBG TEST STRIPS MARKET 2019-2027 ($ MILLION)
  • FIGURE 15 EUROPE SMBG MARKET BY GLUCOSE METER 2019-2027 ($ MILLION)
  • FIGURE 16 EUROPE SMBG GLUCOSE METER MARKET 2019-2027 ($ MILLION)
  • FIGURE 17 EUROPE SMBG LANCETS MARKET 2019-2027 ($ MILLION)
  • FIGURE 18 EUROPE SMBG MARKET SHARE BY END-USER 2018 & 2027 (%)
  • FIGURE 19 EUROPE SMBG MARKET BY HOME SETTING 2019-2027 ($ MILLION)
  • FIGURE 20 EUROPE SMBG MARKET BY CLINICAL 2019-2027 ($ MILLION)
  • FIGURE 21 EUROPE SMBG MARKET BY HOSPITAL 2019-2027 ($ MILLION)
  • FIGURE 22 EUROPE SMBG MARKET SHARE BY APPLICATION 2018 & 2027 (%)
  • FIGURE 23 EUROPE SMBG MARKET BY TYPE 1 DIABETES 2019-2027 ($ MILLION)
  • FIGURE 24 EUROPE SMBG MARKET BY TYPE 2 DIABETES 2019-2027 ($ MILLION)
  • FIGURE 25 EUROPE SMBG MARKET BY GESTATIONAL DIABETES 2019-2027 ($ MILLION)
  • FIGURE 26 PORTER'S FIVE FORCE MODEL
  • FIGURE 27 VALUE CHAIN OF EUROPE CGMS MARKET
  • FIGURE 28 EUROPE CGMS MARKET SHARE BY COUNTRY 2018 & 2027 (%)
  • FIGURE 29 THE UNITED KINGDOM CGMS MARKET 2019-2027($ MILLION)
  • FIGURE 30 THE UNITED KINGDOM SMBG MARKET 2019-2027($ MILLION)
  • FIGURE 31 FRANCE CGMS MARKET 2019-2027 ($ MILLION)
  • FIGURE 32 FRANCE SMBG MARKET 2019-2027($ MILLION)
  • FIGURE 33 GERMANY CGMS MARKET 2019-2027($ MILLION)
  • FIGURE 34 GERMANY SMBG MARKET 2019-2027($ MILLION)
  • FIGURE 35 ITALY CGMS MARKET 2019-2027($ MILLION)
  • FIGURE 36 ITALY SMBG MARKET 2019-2027($ MILLION)
  • FIGURE 37 SPAIN CGMS MARKET 2019-2027 ($ MILLION)
  • FIGURE 38 SPAIN SMBG MARKET 2019-2027($ MILLION)
  • FIGURE 39 RUSSIA CGMS MARKET 2019-2027($ MILLION)
  • FIGURE 40 RUSSIA SMBG MARKET 2019-2027($ MILLION)
  • FIGURE 41 REST OF EUROPE (ROE) CGMS MARKET 2019-2027 ($ MILLION)
  • FIGURE 42 REST OF EUROPE (ROE) SMBG MARKET 2019-2027($ MILLION)
Back to Top